	US 12,187,764 B2
	Affinity carrier using mutant VHH antibody
Yoshihisa Hagihara, Tsukuba (JP); Yoko Akazawa, Ikeda (JP); Yuji Ito, Kagoshima (JP); Tomonari Matsuda, Otsu (JP); Norihiko Kiyose, Kumamoto (JP); Nobuo Miyazaki, Kumamoto (JP); Tetsuo Fukuta, Minato-ku (JP); and Yusaku Mizuguchi, Minato-ku (JP)
Assigned to JSR CORPORATION, Minato-ku (JP)
Appl. No. 17/253,372
Filed by JSR CORPORATION, Minato-ku (JP)
PCT Filed Jun. 20, 2019, PCT No. PCT/JP2019/024404 § 371(c)(1), (2) Date Dec. 17, 2020, PCT Pub. No. WO2019/244961, PCT Pub. Date Dec. 26, 2019.
Claims priority of application No. 2018-117403 (JP), filed on Jun. 20, 2018.
Prior Publication US 2021/0261606 A1, Aug. 26, 2021
Int. Cl. C07K 16/00 (2006.01); C07K 1/22 (2006.01); C07K 16/42 (2006.01); C07K 17/00 (2006.01)

CPC C07K 1/22 (2013.01) [C07K 16/00 (2013.01); C07K 16/4258 (2013.01); C07K 17/00 (2013.01); C07K 2317/569 (2013.01)]

4 Claims

1. An affinity carrier, comprising:

a solid phase carrier; and

an immunoglobulin-binding protein bound to the solid phase carrier,

wherein the immunoglobulin-binding protein comprises a mutant VHH antibody, or a fragment thereof, comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO: 1, the polypeptide has the CDR1 and CDR2 amino acid sequences of SEQ ID NO: 10 and SEQ ID NO: 11, respectively, corresponding to amino acids 26 to 35 and 51 to 65 of SEQ ID NO: 1, the polypeptide has the CDR3 amino acid sequence of SEQ ID NO: 12 corresponding to amino acids 96 to 107 of SEQ ID NO: 1, in which at least at one position selected from the group consisting of amino acids 97, 100, and 102 of SEQ ID NO: 1 has been substituted with histidine, and the immunoglobulin-binding protein binds to an Fab domain of trastuzumab.